MERUS NV (MRUS) Fundamental Analysis & Valuation
NASDAQ:MRUS • NL0011606264
Current stock price
90 USD
-6.92 (-7.14%)
At close:
88.97 USD
-1.03 (-1.14%)
After Hours:
This MRUS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. MRUS Profitability Analysis
1.1 Basic Checks
- In the past year MRUS has reported negative net income.
- In the past year MRUS has reported a negative cash flow from operations.
- MRUS had negative earnings in each of the past 5 years.
- MRUS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- MRUS has a Return On Assets (-42.15%) which is comparable to the rest of the industry.
- MRUS has a better Return On Equity (-49.16%) than 66.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -42.15% | ||
| ROE | -49.16% | ||
| ROIC | N/A |
ROA(3y)-32.12%
ROA(5y)-29.6%
ROE(3y)-43.27%
ROE(5y)-46.91%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- MRUS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. MRUS Health Analysis
2.1 Basic Checks
- MRUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
- MRUS has more shares outstanding than it did 1 year ago.
- MRUS has more shares outstanding than it did 5 years ago.
- MRUS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- MRUS has an Altman-Z score of 29.22. This indicates that MRUS is financially healthy and has little risk of bankruptcy at the moment.
- MRUS's Altman-Z score of 29.22 is amongst the best of the industry. MRUS outperforms 93.21% of its industry peers.
- MRUS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 29.22 |
ROIC/WACCN/A
WACC7.43%
2.3 Liquidity
- MRUS has a Current Ratio of 7.95. This indicates that MRUS is financially healthy and has no problem in meeting its short term obligations.
- MRUS has a better Current ratio (7.95) than 74.15% of its industry peers.
- MRUS has a Quick Ratio of 7.95. This indicates that MRUS is financially healthy and has no problem in meeting its short term obligations.
- With a decent Quick ratio value of 7.95, MRUS is doing good in the industry, outperforming 74.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.95 | ||
| Quick Ratio | 7.95 |
3. MRUS Growth Analysis
3.1 Past
- The earnings per share for MRUS have decreased strongly by -36.92% in the last year.
- The Revenue has grown by 57.54% in the past year. This is a very strong growth!
- The Revenue has been growing slightly by 3.03% on average over the past years.
EPS 1Y (TTM)-36.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.7%
Revenue 1Y (TTM)57.54%
Revenue growth 3Y-9.72%
Revenue growth 5Y3.03%
Sales Q2Q%3.21%
3.2 Future
- Based on estimates for the next years, MRUS will show a very strong growth in Earnings Per Share. The EPS will grow by 26.66% on average per year.
- Based on estimates for the next years, MRUS will show a very strong growth in Revenue. The Revenue will grow by 89.98% on average per year.
EPS Next Y-75.87%
EPS Next 2Y-27.83%
EPS Next 3Y-11.15%
EPS Next 5Y26.66%
Revenue Next Year43.37%
Revenue Next 2Y17.82%
Revenue Next 3Y66.5%
Revenue Next 5Y89.98%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. MRUS Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for MRUS. In the last year negative earnings were reported.
- Also next year MRUS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as MRUS's earnings are expected to decrease with -11.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27.83%
EPS Next 3Y-11.15%
5. MRUS Dividend Analysis
5.1 Amount
- MRUS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MRUS Fundamentals: All Metrics, Ratios and Statistics
90
-6.92 (-7.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31 2025-10-31/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners91.04%
Inst Owner Change0%
Ins Owners0.22%
Ins Owner Change-2.86%
Market Cap6.83B
Revenue(TTM)56.61M
Net Income(TTM)-381.00M
Analysts70.43
Price Target99.48 (10.53%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-36.37%
Min EPS beat(2)-83.38%
Max EPS beat(2)10.64%
EPS beat(4)2
Avg EPS beat(4)-12.3%
Min EPS beat(4)-83.38%
Max EPS beat(4)51.7%
EPS beat(8)3
Avg EPS beat(8)-15.65%
EPS beat(12)6
Avg EPS beat(12)-12.87%
EPS beat(16)10
Avg EPS beat(16)1.31%
Revenue beat(2)1
Avg Revenue beat(2)-0.47%
Min Revenue beat(2)-37.2%
Max Revenue beat(2)36.26%
Revenue beat(4)2
Avg Revenue beat(4)55.58%
Min Revenue beat(4)-37.2%
Max Revenue beat(4)232.22%
Revenue beat(8)3
Avg Revenue beat(8)27.5%
Revenue beat(12)6
Avg Revenue beat(12)19.96%
Revenue beat(16)9
Avg Revenue beat(16)16.38%
PT rev (1m)0%
PT rev (3m)5.25%
EPS NQ rev (1m)1.35%
EPS NQ rev (3m)5.18%
EPS NY rev (1m)0.77%
EPS NY rev (3m)4.56%
Revenue NQ rev (1m)-2.85%
Revenue NQ rev (3m)-4.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 120.6 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 8.81 | ||
| P/tB | 8.83 | ||
| EV/EBITDA | N/A |
EPS(TTM)-5.34
EYN/A
EPS(NY)-5.41
Fwd EYN/A
FCF(TTM)-4.2
FCFYN/A
OCF(TTM)-4.19
OCFYN/A
SpS0.75
BVpS10.22
TBVpS10.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -42.15% | ||
| ROE | -49.16% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-32.12%
ROA(5y)-29.6%
ROE(3y)-43.27%
ROE(5y)-46.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 24.97% | ||
| Cap/Sales | 1.08% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.95 | ||
| Quick Ratio | 7.95 | ||
| Altman-Z | 29.22 |
F-Score4
WACC7.43%
ROIC/WACCN/A
Cap/Depr(3y)275.81%
Cap/Depr(5y)194.96%
Cap/Sales(3y)10.83%
Cap/Sales(5y)7.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-36.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.7%
EPS Next Y-75.87%
EPS Next 2Y-27.83%
EPS Next 3Y-11.15%
EPS Next 5Y26.66%
Revenue 1Y (TTM)57.54%
Revenue growth 3Y-9.72%
Revenue growth 5Y3.03%
Sales Q2Q%3.21%
Revenue Next Year43.37%
Revenue Next 2Y17.82%
Revenue Next 3Y66.5%
Revenue Next 5Y89.98%
EBIT growth 1Y-60.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-48.55%
EBIT Next 3Y-2.47%
EBIT Next 5YN/A
FCF growth 1Y-123.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-133.19%
OCF growth 3YN/A
OCF growth 5YN/A
MERUS NV / MRUS Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for MERUS NV?
ChartMill assigns a fundamental rating of 4 / 10 to MRUS.
What is the valuation status for MRUS stock?
ChartMill assigns a valuation rating of 0 / 10 to MERUS NV (MRUS). This can be considered as Overvalued.
What is the profitability of MRUS stock?
MERUS NV (MRUS) has a profitability rating of 1 / 10.
What is the financial health of MERUS NV (MRUS) stock?
The financial health rating of MERUS NV (MRUS) is 8 / 10.